Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 8/20 | 0.37 |
| ▸ | CCR5 | P51681 | 2/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181117 | 0.90 | SLC5A2 (0.45) | SLC5A2CCR5SLC5A1ACACBSLC6A4 | |
| SCHEMBL181205 | 0.84 | SLC5A2 (0.48) | SLC5A2SLC5A1SLC6A4 | |
| SCHEMBL181059 | 0.76 | L3MBTL1 (0.45) | — | |
| SCHEMBL2638119 | 0.75 | SLC5A2 (0.59) | SLC5A2SLC5A1SLC6A4 | |
| SCHEMBL29740488 | 0.75 | SLC5A2 (0.59) | SLC5A2SLC5A1SLC6A4 | |
| SCHEMBL24989748 | 0.75 | SLC5A2 (0.46) | SLC5A2SLC5A1ACACBHRH1 | |
| SCHEMBL2638121 | 0.75 | SLC5A2 (0.59) | SLC5A2SLC5A1SLC6A4 | |
| SCHEMBL29882671 | 0.75 | SLC5A2 (0.59) | SLC5A2SLC5A1SLC6A4 | |
| SCHEMBL30476132 | 0.75 | SLC5A2 (0.46) | SLC5A2SLC5A1ACACBHRH1 | |
| SCHEMBL2870718 | 0.75 | SLC5A2 (0.59) | SLC5A2SLC5A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334687-B9 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2334687-B1 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8080580-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2334687-A1 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | Pfizer Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010023594-A1 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056618-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056618-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | CACNA1G 656/4885CACNA1H 797/4885CACNA1I 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.